195 related articles for article (PubMed ID: 35280444)
1. Is Anti-NXP2 Autoantibody a Risk Factor for Calcinosis and Poor Outcome in Juvenile Dermatomyositis Patients? Case Series.
Toplak N; Pimpale Chavan P; Rosina S; Dallos T; Rotem Semo O; Aguiar CL; Khubchandani R; Ravelli A; Patwardhan A
Front Pediatr; 2021; 9():810785. PubMed ID: 35280444
[TBL] [Abstract][Full Text] [Related]
2. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
Tansley SL; Betteridge ZE; Shaddick G; Gunawardena H; Arnold K; Wedderburn LR; McHugh NJ;
Rheumatology (Oxford); 2014 Dec; 53(12):2204-8. PubMed ID: 24987158
[TBL] [Abstract][Full Text] [Related]
3. Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population.
Manwatkar A; Padiyar S; Nair A; Jha A; Kumar S; Yadav B; Prakash JAJ; Das JK; Mathew J
Clin Rheumatol; 2023 Dec; 42(12):3289-3297. PubMed ID: 37801141
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children.
Wang X; Ding Y; Zhou Z; Hou J; Xu Y; Li J
Pediatr Rheumatol Online J; 2021 Jan; 19(1):6. PubMed ID: 33407621
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal perforation in anti-NXP2 antibody-associated juvenile dermatomyositis: case reports and a review of the literature.
Xu Y; Ma X; Zhou Z; Li J; Hou J; Zhu J; Kang M; Lai J; Li X
Pediatr Rheumatol Online J; 2021 Jan; 19(1):2. PubMed ID: 33407602
[TBL] [Abstract][Full Text] [Related]
6. Juvenile dermatomyositis associated with autoantibodies to small ubiquitin-like modifier activating enzyme: a report of 4 cases from North India and a review of literature.
Vignesh P; Barman P; Basu S; Mondal S; Ishran B; Kumrah R; Dod A; Garg R; Rawat A; Singh S
Immunol Res; 2023 Feb; 71(1):112-120. PubMed ID: 36278969
[TBL] [Abstract][Full Text] [Related]
7. Recent research on myositis-specific autoantibodies in juvenile dermatomyositis.
He L
Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1064-1068. PubMed ID: 34719424
[TBL] [Abstract][Full Text] [Related]
8. Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis.
Sag E; Demir S; Bilginer Y; Talim B; Haliloglu G; Topaloglu H; Ozen S
Semin Arthritis Rheum; 2021 Feb; 51(1):95-100. PubMed ID: 33360233
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the clinical characteristics and therapeutic effect of refractory juvenile dermatomyositis to tofacitinib].
Zhou QF; Luo Y; He TY; Ling JY; Xu YB; Yang J; Xia Y
Zhonghua Er Ke Za Zhi; 2023 Jun; 61(6):538-542. PubMed ID: 37312466
[No Abstract] [Full Text] [Related]
10. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.
Ichimura Y; Matsushita T; Hamaguchi Y; Kaji K; Hasegawa M; Tanino Y; Inokoshi Y; Kawai K; Kanekura T; Habuchi M; Igarashi A; Sogame R; Hashimoto T; Koga T; Nishino A; Ishiguro N; Sugimoto N; Aoki R; Ando N; Abe T; Kanda T; Kuwana M; Takehara K; Fujimoto M
Ann Rheum Dis; 2012 May; 71(5):710-3. PubMed ID: 22258483
[TBL] [Abstract][Full Text] [Related]
11. Nodular Regenerative Hyperplasia of the liver in Juvenile Dermatomyositis.
Lanis A; Volochayev R; Kleiner DE; Vittal A; Heller T; Rider LG; Shenoi S
Pediatr Rheumatol Online J; 2022 Apr; 20(1):30. PubMed ID: 35443665
[TBL] [Abstract][Full Text] [Related]
12. Comparison of clinical and laboratory features and treatment responses in patients with clinically amyopathic juvenile dermatomyositis and classical juvenile dermatomyositis.
Gezgin Yıldırım D; Baglan E; Güngörer V; Yıldız C; Tuncez S; Bülbül M; Acar B; Bakkaloğlu SA
Int J Rheum Dis; 2023 Aug; 26(8):1504-1511. PubMed ID: 37288472
[TBL] [Abstract][Full Text] [Related]
13. An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations.
Fredi M; Cavazzana I; Ceribelli A; Cavagna L; Barsotti S; Bartoloni E; Benucci M; De Stefano L; Doria A; Emmi G; Fabris M; Fornaro M; Furini F; Giudizi MG; Govoni M; Ghirardello A; Iaccarino L; Iannone F; Infantino M; Isailovic N; Lazzaroni MG; Manfredi M; Mathieu A; Marasco E; Migliorini P; Montecucco C; Palterer B; Parronchi P; Piga M; Pratesi F; Riccieri V; Selmi C; Tampoia M; Tripoli A; Zanframundo G; Radice A; Gerli R; Franceschini F;
Clin Rev Allergy Immunol; 2022 Oct; 63(2):240-250. PubMed ID: 35092577
[TBL] [Abstract][Full Text] [Related]
14. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
15. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
16. Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody.
Yan TT; Zhang X; Yang HH; Sun WJ; Liu L; Du Y; Xue J
Clin Rheumatol; 2021 Sep; 40(9):3695-3702. PubMed ID: 33712891
[TBL] [Abstract][Full Text] [Related]
17. Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis.
Li L; Liu C; Cheng L; Yan S; Chen H; Li Y
Clin Rheumatol; 2021 Mar; 40(3):819-832. PubMed ID: 32681367
[TBL] [Abstract][Full Text] [Related]
18. Biologic drugs in the treatment of juvenile dermatomyositis: a literature review.
Sener S; Cam V; Ozen S; Batu ED
Clin Rheumatol; 2024 Feb; 43(2):591-602. PubMed ID: 37582998
[TBL] [Abstract][Full Text] [Related]
19. Early-onset juvenile dermatomyositis: A tertiary referral center experience and review of the literature.
Sener S; Basaran O; Batu ED; Sag E; Oz S; Talim B; Bilginer Y; Haliloglu G; Ozen S
Semin Arthritis Rheum; 2023 Feb; 58():152133. PubMed ID: 36434896
[TBL] [Abstract][Full Text] [Related]
20. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.
Walling HW; Gerami P; Sontheimer RD
Paediatr Drugs; 2010; 12(1):23-34. PubMed ID: 20034339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
